vendredi 14 décembre 2012

Press Review (December 15, 2012) – Revue de presse (15 décembre 2012)




When Fighting Cancer Isn't Worth It
The most aggressive treatments currently available don't guarantee success, and they aren't right for everyone.
By Mary Mulcahy. In The Atlantic

In challenge to personalized cancer care, DNA isn't all-powerful
The cancer cells were not behaving the way the textbooks say they should. Some of the cells in colonies that were started with colorectal tumor cells were propagating like mad; others were hardly multiplying. Some were dropping dead from chemotherapy and others were no more slowed by the drug than is a tsunami by a tissue. Yet the cells in each "clone" all had identical genomes, supposedly the all-powerful determinant of how cancer cells behave.
By Sharon Begley. In Reuters

'Two-faced' cells discovered in colon cancer
Immune cells can suppress or promote tumor growth.
In EurekAlert (press release)

Cancer stem cells isolated from kidney tumors
Scientists have isolated cancer stem cells that lead to the growth of Wilms' tumours, a type of cancer typically found in the kidneys of young children. The researchers have used these cancer stem cells to test a new therapeutic approach that one day might be used to treat some of the more aggressive types of this disease. The results are published online in EMBO Molecular Medicine.
In EurekAlert (press release)

Researchers find new culprit in castration-resistant prostate cancer
Previously unknown protein function could be a treatment target.
In EurekAlert (press release)

New technique for minimally invasive robotic kidney cancer surgery
Urologists at Henry Ford Hospital have developed a new technique that could make minimally invasive robotic partial nephrectomy procedures the norm, rather than the exception for kidney cancer patients. The technique spares the kidney, eliminates long hospital stays and provides better outcomes by giving the surgeon more time to perform the procedure.
In EurekAlert (press release)



Aspirin could be prescribed to cut cancer cases
Aspirin could be prescribed to patients at risk of developing cancer as part of new measures to combat the disease, the Department of Health has disclosed.
By Tom Rowleyraph.co.uk

Rembrandt's Bathsheba did not have breast cancer after all: cientists cast new light on famous painting
In 1654, Rembrandt van Rijn painted his famous Bathsheba, which depicts King David's wife naked at her bath. The painting has been regarded as an icon for breast cancer since the 1980s, after two Australian surgeons had interpreted the blue mark on her breast as breast cancer and wrote an article about it. Now, with the help of computer simulations, researchers from the MIRA research institute at the University of Twente have demonstrated that it is 'highly unlikely' that the blue mark on Bathsheba's breast really was caused by the disease.
In Phys Org

Substance With Promising in Vitro Anti-Cancer Effects Synthesized: Substance Found in Tiny Amounts in Chinese Medicinal Herb
In science's equivalent of ascending Mt. Everest, researchers are reporting success in one of the most difficult challenges in synthetic chemistry -- a field in which scientists reproduce natural and other substances from jars of chemicals in a lab.
In Science Daily (press release)


Cancer : une fillette en rémission grâce au sida
Une thérapie génique encore expérimentale a permis à Emma Whitehead, qui souffrait d'une leucémie avancée, de connaître un spectaculaire rétablissement.
Dans Le Nouvel Observateur

ÉTUDE. Le café limiterait les risques de mortalité de certains cancers
Boire plus de quatre tasses de café par jour pourrait diminuer de moitié le risque de décès du cancer oro-pharyngé (relatif à la bouche et au pharynx), selon une étude menée par l'American Cancer Society, publiée dans le dernier numéro du American Journal of Epidemiology.
Par Stanislas Wang-Genh. Dans Le Huffington Post

Cancer du sein : certaines femmes recevront 10 ans de tamoxifène au lieu de 5
L'allongement de la durée du traitement par tamoxifène en adjuvant à 10 ans permet de réduire le risque de récidive tardive du cancer du sein avec expression des récepteurs aux estrogènes (ER+) et améliore la survie, selon l'étude ATLAS (Adjuvant Tamoxifen - Longer Against Shorter) présentée au San Antonio Breast Cancer Symposium (SABCS) et publiée simultanément dans le Lancet.
Par Aude Lecrubier. Dans Medscape-France 

Cancer du col: faire un frottis après test HPV positif est gagnant‎
Selon une étude prospective finlandaise , le dépistage du cancer du col de l'utérus par la recherche de l'ADN du papillomavirus humain (HPV), couplée à un examen cytologique par frottis cervico-utérin en cas de résultat positif, permet de détecter davantage de lésions précancéreuses, comparativement au frottis seul.
Par Vincent Richeux. Dans Medscape-France 

Cancer de la vessie : le tabagisme, premier facteur de risque
Le cancer de la vessie prend de plus en plus d’ampleur en Algérie. Contrairement à l’Europe, les tumeurs de la vessie constituent au Maghreb le premier cancer urologique après celui de la prostate.
Par Djamila Kourta. Dans El Watan

Aucun commentaire:

Enregistrer un commentaire